Trial Search Results

A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors

In this study, patients with advanced solid tumors will undergo [18F]F AraG PET/CT imaging to assess for changes in tracer uptake following treatment with CkIT.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

CellSight Technologies, Inc.

Collaborator: Stanford University

Intervention(s):

  • Drug: [18F]F-AraG

Phase:

Phase 2

Eligibility


Inclusion Criteria:

   - Solid tumor with planned CkIT

   - Must be >18 years old

   - Signed Informed Consent Form

   - Patient must have two qualifying lesions

Exclusion Criteria:

   - Patient is pregnant or breast feeding

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Maria Isabel Galvez Leonio
650-723-0371